2-Bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Catalog No. :
ACNORP116
CAS No. :
1402172-61-5
Molecular Formula :
C12H17BBrNO2
Molecular Weight :
297.99

IUPAC Name:2-bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2-Bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$488.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
IUPAC Name2-bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
MDL No.MFCD21364809
Molecular FormulaC12H17BBrNO2
Molecular Weight297.99
SMILESCC1(C)C(C)(C)OB(C2=CC(Br)=NC=C2C)O1
InChI KeyTUWUKLVYSRAECA-UHFFFAOYSA-N
Synonym2-Bromo-5-methylpyridine-4-boronic acid pinacol ester;Pyridine, 2-bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1402172-61-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACNORP116 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACBCHP729 route compound structure diagram
    ACBCHP7291227577-26-5 In Stock
  4. Then
  5. ACNORP116 route product structure diagram
    ACNORP1161402172-61-5
Inquiry

2. ACNORP116 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWLEF012 route compound structure diagram
    ACWLEF01276-09-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNORP116 route product structure diagram
    ACNORP1161402172-61-5
Inquiry

Comments (0)